Key result
Transfemoral TAVR appeared superior to SAVR for long-term survival in patients with aortic stenosis and chronic liver disease, despite high periprocedural mortality for both procedures.
Why the study?
Does transfemoral TAVR improve long-term survival compared to SAVR in patients with aortic stenosis and chronic liver disease?
Does transfemoral TAVR improve long-term survival compared to SAVR in patients with aortic stenosis and chronic liver disease?
Transfemoral TAVR may offer better long-term survival than SAVR in patients with aortic stenosis and chronic liver disease, though periprocedural mortality remains high for both.
Chronic liver disease is associated with increased operative risk of open-heart surgery. In this study, transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) carried high periprocedural mortality, but transfemoral TAVR appeared to be superior to SAVR in terms of long-term survival. Better risk stratification tools are needed for patients with liver dysfunction to avoid futile TAVR and SAVR procedures.
No takes yet. Share an insight, caveat, or question.
Tarantini et al. (2020) conducted an editorial in Aortic stenosis with chronic liver disease. Transfemoral TAVR vs. SAVR was evaluated on Long-term survival and periprocedural mortality. Transfemoral TAVR appeared superior to SAVR for long-term survival in patients with aortic stenosis and chronic liver disease, despite high periprocedural mortality for both procedures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: